NPPA seeks clarification on license status from Clotrimazole mouth paint manufacturers

Published On 2022-02-01 12:37 GMT   |   Update On 2022-02-01 12:40 GMT
Advertisement

In relation to the fixation of ceiling price of antifungal drug clotrimazole 1% mouth paint, the National Pharmaceutical Pricing Authority (NPPA) panel has sought to get a clarification of approval of license status from the manufacturers and marketer of the drug.

This came during the 38th meeting of 'Multidisciplinary Committee of Experts' meeting which was held on 24.01.2022 through video conference.

Advertisement

For more information, check out the full story on the link below:

NPPA seeks clarifications regarding ceiling price fixation of Clotrimazole mouth paint




Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News